BML, Inc. (4694.T)
Tokyo · JPY · Healthcare · Diagnostics & Research
¥3,820 (+0.13%) as of
Key statistics
- Market cap
- 143.19B
- P/E (TTM)
- 18.32
- Forward P/E
- 25.71
- EPS (TTM)
- 208.54
- Dividend yield
- 3.28%
- 52-week range
- 3,370.00 – 4,385.00
- Beta
- 0.22
- Revenue (TTM)
- 151.27B
- Profit margin
- 5.20%
- Analyst target
- ¥3,800
- Volume
- 47.50k
About BML, Inc.
BML, Inc. provides contract clinical testing and related services in Japan. The company offers routine laboratory testing, such as biochemical and hematologic examination; special laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispensing. It also provides contract clinical testing, including endocrine, plasma protein, biochemical, viral, immunoserological, hematological, cellular immunity, bacteriological, and histopathological, pathological, and cytological tests; specimen receiving service; and medical information system services, which include electronic medical charts for clinics without beds. In addition, the company is involved in manufacturing and supply services for medical equipment and supplies; real estate leasing and insurance agency business; providing food hygiene inspection and food consulting services; and dispensing pharmacy services. The company was incorporated in 1955 and is headquartered in Tokyo, Japan.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Tokyo, Japan
- Employees
- 4,612
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.